Auron Therapeutics is a pioneering brand founded by an experienced team of physicians and scientists who specialize in developing effective differentiation therapies for patients in need. With a strong emphasis on innovation, Auron has harnessed their initial successes to create a groundbreaking multi-omic computational platform. This platform has provided them with a unique understanding of the dysregulated differentiation pathways in cancer cells, leading to the identification of novel drug targets that can be applied across various tumor indications.

Led by their Chief Scientific Officer, Dr. David Millan, the Auron team is motivated and dedicated to transforming the lives of patients and their families. Their vision is to revolutionize the treatment paradigm for a wide range of cancer types, offering hope and a new approach where there are currently no effective treatment options available.

With a strong leadership team and a roster of talented individuals, Auron Therapeutics is at the forefront of cutting-edge cancer research and the development of transformative medicines